||Etiology Of Alkylator-Induced Myeloid Leukemia
||CALGB 9665: The CALGB Leukemia Tissue Bank
||CALGB 9862: Molecular Genetic Features of Acute Lymphoblastic Leukemia (Optional Companion to CALGB 19802)
||S0535: A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
||A University of Chicago Leukemia Registry Protocol.
||AML08: A Phase III Randomized Trial of Clofarabine, Plus Cytarabine Versus Conventional Induction Therapy and a Phase III Study of Natural Killer Cell Transplantation in Patients With Newly Diangosed Acute Myeloid Leukemia
||Molecular characterization of hematopoietic malignancies
||A Phase I Dose-Escalation Study of LY2090314 in Patients with Acute Leukemia.
||S0805: Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) (a BMT Study)
||A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
||E1908: A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients using Alemtuzumab, and Rituximab
||COG AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
||CALGB 10701:A Phase II Study of Dasatinib (Sprycel®) (IND #73969, NSC #732517) as Primary Therapy followed by Transplantation for Adults >/= 50 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG, SWOG and NCIC CTG
||Evaluation of patients with hematopoietic malignancies and their family members for mutations in RUNX1, CEBPA, and p53.
||A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy (V212-011)
||A Phase III, Multicenter, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine (Protocol 04-21).
||Randomized phase I study combining suppression of T regulatory cells with WT1 vaccine therapy for AML patients in complete remission
||An Open-Label, Phase 1 Study of Inotuzumab Ozogamicin in Subjects with Relapsed or Refractory CD22-Positive Acute Lymphocytic Leukemia.
||A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
||CALGB 11001: A Phase II Study Incorporating Sorafenib Into The Therapy of Patients ≥ 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
||A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk
Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
||A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Relapsed or Refractory Acute Lymphoblastic Leukemia.
||An open label assessment of safety and efficacy of Ruxolitinib (INCB018424) in subjects with primary myelofibrosis, post essential thrombocythemia-myelofibrosis and post polycythemia vera-myelofibrosis who have platelet counts of 50 x109/L to 100 x109/L.
||Pharmacokinetics, Safety and Tolerability of Intravenous Posaconazole Solution followed by Oral Posaconazole Suspension (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1B) (P05520)
||An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)
||A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects >/= 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
||CALGB 11002: A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients >/= 60 Years Old With Acute Myeloid Leukemia (AML)
||Phase I investigation of the feasibility of combining 5-azacytidine with highdose
cytarabine (HiDAC) and mitoxantrone chemotherapy in a sequential manner
for remission induction in high-risk acute myelogenous leukemia (AML)
||A Phase I, Open- Label, Multicenter Clinical Trial to Evaluate the
Safety and Immunogenicity of V212/Inactivated Varicella- Zoster Virus (VZV)
Vaccine in Adults with Hematologic Malignancies Receiving Treatment with
Anti- CD20 Monoclonal Antibodies (V212- 013)
||A phase 1b study to evaluate the safety and preliminary efficacy of PF-04449913, an oral hedgehog inhibitor, in combination with intensive chemotherapy, low dose ara-C or decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome.
||A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
||S1117, A Randomized Phase II Study of Azacitidine in Combination withLenalidomide (NSC-703813)
vs. Azacitidine Alone vs. Azacitidine in
Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic
Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
||A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase